GVHD continues to be a major complication after allogeneic hematopoietic stem cell transplantation even when the recipient is given immunosuppression for the prophylaxis of this severe disease. There have been many advances in the prevention and treatment of GVHD, using compounds such as cyclosporine, FK506, mycophenolate mofetil or monoclonal IL-2 receptor antagonist. New strategies seem to include sequential therapy involving the blocking of both endogenous cytokines and alloreactive donor cells. However, further clinical and laboratory studies are needed in order to improve the therapy of established GVHD. Bone Marrow Transplantation (2000) 25, Suppl. 2, S12-S15.
1 the pathophysiology of acute GVHD can be summarized as a three-step process. The earliest phase of acute GVHD may start with the transplant conditioning regimen by damaging and activating host tissues. Activated host cells secrete inflammatory cytokines such as tumor necrosis factor-␣, interleukin (IL)-1, granulocyte-macrophage colony-stimulating factor (GM-CSF) and many other substances. 2 The second phase of acute GVHD consists of donor T cell activation. It includes antigen presentation, activation of individual T cells, as well as proliferation and differentiation of activated T cells. In the presence of mediators such as IL-12, a T-helper 1 (Th1) subset of T cells seems to be formed. 3 Cytokines such as IL-2 and IFN-␥ are produced in response to alloantigens and play a central role in the pathophysiology of acute GVHD. 4 In phase three of acute GVHD, T cells may then kill target cells through Fas-Fas ligand interactions perforin-granzyme B and the production of cytokines. 5 In addition, the other effectors such as granulocytes, monocytes and natural killer (NK) cells may cause both specific and non-specific injury.
The pathophysiology of chronic GVHD is often considered as an autoimmune process because of similarities to several autoimmune disorders, especially collagen-vascular disease. T cells from animals with experimentally induced chronic GVHD are specific for a common determinant of MHC class II molecules. 6 These T cells produce other pat- 
Incidence of developing GVHD
The risks of developing acute GVHD and chronic GVHD after marrow unrelated donor (MUD), as well as after HLAmismatched related transplantations are significantly higher than after a hemopoietic stem cell transplantation (HSCT) from an HLA-matched sibling. 7 The combination of immunosuppressive drugs, CsA, prednisolone and a short course of MTX is an effective regimen for prevention of GVHD after BMT. 8 However, the incidence reported for acute GVHD grade II to IV after transplantation from HLA matched MUD is 78% and the incidence for grade III and IV is 36%. The incidence of chronic GVHD is 64%. 9 Since GVHD contributes to morbidity and mortality after MUD BMT, more effective prophylaxis and therapy of this severe complication is needed.
Diagnosis and grading
Acute GVHD is a clinicopathological syndrome involving the skin, liver and gut. 10 In general, grade I aGVHD has a favorable prognosis and does not need therapy. Grade II GVHD is a moderately severe condition that requires therapy and usually consists of multiorgan disease. Grade III GVHD is a severe multiorgan disease and grade IV is usually life-threatening or fatal.
Clinicopathological classification of chronic GVHD considers limited and extensive chronic GVHD. 11 The skin is the main organ involved with two different forms of presentation: the early phase resembles lichen planus; during later phases poikiloderma is observed, in some patients in the absence of significant inflammation and in other patients with inflammation in eccrine coils and pilar resulting in fibrosis and scleroderma. Hepatic chronic GVHD may be associated with cholestatic abnormalities. Ophthalmic symptoms include irritation, burning and pain. Oral dryness, sensitivity to acidic foods and pain indicate chronic GVHD of oral mucous membranes. Bronchiolotis obliterans is also a common form of chronic GVHD of the lung caused by obliteration of the small bronchioles. 
Treatment of established acute GVHD

Primary treatment
Treatment is necessary for grade II-IV aGVHD and consists of continuing the original immunosuppressive prophylaxis (cyclosporine A (CsA) or tacrolimus (FK506)) and addition of methylprednisolone (MP). 12 Responses have been observed at dosages from 1 to 60 mg/kg/day, although most clinicians employ a tapering schedule of 2 mg/kg/day MP divided in two doses. Recently, an Italian group for bone marrow transplantation reported 13 the results of prospective, multicenter, randomized trials designed to test the effect of a low-dose (2 mg/kg/day) vs a high-dose (10 mg/kg/day) MP on aGVHD given early at the onset of disease. They showed that early treatment of aGVHD with a high dose of MP did not improve the response rate as compared with the low dose, or prevent evolution to severe aGVHD. In the last few years, several pilot studies have reported useful new modalities for aGVHD treatment. Recently, we published the results for 17 patients with aGVHD treated with mycophenolate mofetil (MMF) and have shown that MMF can be used safely for the treatment of aGVHD.
14 In addition, the MMF therapy resulted in significant dose reduction of prednisolone for the treatment of GVHD. 15 We have continued with this study and have treated a group of 48 patients with MMF among which 36 patients had acute GVHD and 12 patients chronic GVHD. The main patient characteristics and the response rate are given in Table 1 . A controlled study of the anti-IL-2R antibody in 69 patients showed no overall benefit in response or survival in patients treated with antibody and CsA/MP compared with the patients treated with CsA/MP. 16 
Secondary treatment
Patients in whom the initial therapy failed, defined as progression after 3 days, no change after 7 days, or incomplete response after 14 days of MP treatment, received different salvage regimens. Treatment with OKT-3 monoclonal antibody showed some benefit, with 65% response after treatment cycles and 25% patients alive at 1 year. 17 Used as a salvage treatment in patients with acute GVHD, MMF seems not to be successful in keeping GVHD under control. 18 Antibody therapy specific for the IL-2 receptor has been developed. The results have shown complete and partial response rates in 10 to 80% of patients. 19 Our preliminary results with a humanized anti-Tac antibody to the IL-2 receptor (daclizumab) obtained in 11 patients with aGVHD (Table 2) showed an initial response in 60% of the patients. 20 However, 1 year survival was poor with 18% of the patients. Therapies to downregulate IL-1 yielded similar response rates of 60% in pilot trials. 21 Salvage therapy with murine immunoglobulin M antibody directed against activated T and B lymphocytes and NK cells, CBL-1 22 gave a response in nine of the 10 patients studied. 
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Treatment of established chronic GVHD
Primary treatment
Primary treatment of chronic GVHD in both standard-and high-risk patients includes the addition of CsA to prednisone. The results showed that 3-year survival (KaplanMeier) is achieved in 80% of standard risk and 48% of high risk patients. 23 The use of thalidomide as a primary treatment in high-risk patients has been described. 24 The 3-year survival was 48% in 21 patients who received primary treatment.
Secondary treatment
The use of thalidomide as salvage therapy for treatment of chronic GVHD has also been published. 25 Sustained response was observed in only 20% of the patients. Reversible side-effects, leading to discontinuation of the drug and reduction in the number of patients who could benefit from treatment, occurred in 36% of the patients. Chronic GVHD was also treated with clofazimine in an open-label phase II clinical trial. Over 50% of the patients with skin involvement, flection contractures or oral manifestations achieved complete or partial remission. 26 Refractory cutaneous chronic GVHD has been treated with psoralen and ultraviolet A irradiation (PUVA). 27 Last year, the successful use of extracorporeal photochemotherapy in the treatment of severe chronic GVHD was reported with an 80% response rate. 28 In conclusion, the control of GVHD is one of the most important issues in HSCT. The problems associated with current GVHD treatment, demonstrate the need for alternative methods to control GVHD and improve HSCT outcomes. One of these methods could be the use of donor T cells expressing a 'suicide' gene such as the thymidine kinase gene of the herpes simplex virus. The sensitivity of these gene-modified T cells to ganciclovir could allow the possibility of better control of severe GVHD.
